Cybin Announces Nasdaq Listing Transfer and Ticker Change to HELP

Cybin Inc., a clinical-stage pharmaceutical company developing next-generation mental health treatments, announced plans to voluntarily transfer its U.S. stock exchange listing from NYSE American to the Nasdaq Global Market. The company expects its common shares to cease trading on NYSE American at market close on Jan. 4, 2026, and to begin trading on Nasdaq at market open on Jan. 5, 2026, at which time the ticker symbol will change from "CYBN" to "HELP." Cybin will remain listed on Cboe Canada and will also trade under the "HELP" ticker on that exchange beginning Jan. 5, 2026.

This move represents a strategic shift for Cybin as it advances its clinical programs targeting major mental health conditions. The company is developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder. This compound has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address significant unmet medical needs. Cybin is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder, with additional research pipeline compounds focused on 5-HT receptors.

The listing transfer to Nasdaq, a market known for technology and healthcare companies, could provide Cybin with greater visibility among investors focused on innovative medical treatments. The ticker symbol change to "HELP" directly reflects the company's mission to revolutionize mental healthcare by developing new treatment options for people suffering from mental health conditions. With promising class-leading data, Cybin aims to change the mental health treatment landscape through novel drugs that provide effective and durable results for patients.

For investors seeking additional information, the latest news and updates relating to Cybin are available in the company's newsroom at https://ibn.fm/CYBN. The full press release detailing the listing transfer can be viewed at https://ibn.fm/pcrpA. This transition comes as mental health treatment represents a growing area of pharmaceutical innovation, with companies like Cybin working to address what they describe as "large unmet need" in mental healthcare through novel therapeutic approaches.